secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-08-11T20:07:16+00:00
Accession:  0001193125-26-344608
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT reports Q2 2026 net loss of $56.5M; cash runway into 2028
--------------------------------------------------------------

- Net loss widened to $56.5M in Q2 2026 vs $28.4M in Q2 2025; R&D up to $49.2M from $27.4M.
- G&A rose to $11.0M from $2.7M, reflecting standalone operations, de-SPAC, and one-time severance.
- Cash, equivalents and marketable securities $344.1M as of June 30, 2026; expected runway into 2028.
- Initiated dosing of BBO-11818 + cetuximab and BBO-11818 + BBO-10203 combos; also BBO-8520 + BBO-10203.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/0001193125-26-344608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/bbot-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer